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Assisted reproductive technology (ART) is a common treatment of choice for many couples facing infertility issues,
be it due to male or female factor, or idiopathic. Employment of ART techniques, however, come with its own
challenges as the in vitro environment is not nearly as ideal as the in vivo environment, where reactive oxygen
species (ROS) build-up leading to oxidative stress is kept in check by the endogenous antioxidants system. While
physiological amounts of ROS are necessary for normal reproductive function in vivo, in vitro manipulation of
gametes and embryos exposes these cells to excessive ROS production either by endogenous or exogenous
environmental factors. In this review, we discuss the sources of ROS in an in vitro clinical setting and the influence
of oxidative stress on gamete/embryo quality and the outcome of IVF/ICSI. Sources of ROS and different strategies
of overcoming the excessive generation of ROS in vitro are also highlighted. Endogenously, the gametes and the
developing embryo become sources of ROS. Multiple exogenous factors act as potential sources of ROS, including
exposure to visible light, composition of culture media, pH and temperature, oxygen concentration, centrifugation
during spermatozoa preparation, ART technique involving handling of gamete/embryo and cryopreservation
technique (freeze/thawing process). Finally, the use of antioxidants as agents to minimize ROS generation in the
in vitro environment and as oral therapy is highlighted. Both enzymatic and non-enzymatic antioxidants are
discussed and the outcome of studies using these antioxidants as oral therapy in the male or female or its use
in vitro in media is presented. While results of studies using certain antioxidant agents are promising, the current
body of evidence as a whole suggests the need for further well-designed and larger scale randomized controlled
studies, as well as research to minimize oxidative stress conditions in the clinical ART setting.
Keywords: Reactive oxygen species, Oxidative stress, Antioxidants, Assisted reproductive technology, In vitro
fertilization, Intracytoplasmic sperm injection, ART outcomeBackground
Infertility, a disease of the reproductive system defined by
the failure to achieve a clinical pregnancy after 12 months
or more of regular unprotected sexual intercourse [1],
affects 15% of all couples, with nearly a quarter of cases
being without an identifiable causative factor [2]. Medical
treatment for infertility include in vitro fertilization (IVF)
and intracytoplasmic sperm injection (ICSI), which are
the two most common interventions used in assisted re-
productive technology (ART) [3].
Successful ART outcome, including fertilization and
clinical pregnancy resulting in live birth, is influenced by* Correspondence: agarwaa@ccf.org
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unless otherwise stated.a multitude of factors - among which reactive oxygen
species (ROS) plays a significant role [4]. The consequent
development of oxidative stress is among the chief causes
of defective gametes or poorly-developing embryos in
ART [5]. This occurs because the IVF process performed
in a clinical laboratory setting cannot recreate the exact
conditions under which natural fertilization takes place [6].
Among the crucial factors lacking in assisted reproduction
procedures is the tight control of ROS levels maintained
within physiological concentration by antioxidants in vivo
[3].
In order to optimize gamete/embryo quality and im-
prove ART outcome, deliberate preventive measures are
necessary to reduce any incidental build-up of ROS leading
to oxidative stress development during ART. One method
to achieve this would be by enhancing the antioxidantl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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assault of oxidation. In this paper, we will review the
sources of oxidative stress and the use of antioxidants in a
clinical ART setting to minimize the detrimental effects of
oxidative stress on gamete and/or embryo during assisted
reproduction.
Free radicals, reactive oxygen species and
oxidative stress
Free radicals are molecules or atoms with an odd or
unpaired number of valence electrons. Although necessary
for physiological bodily functions, free radicals are harmful
in larger amounts and are involved in the pathophysiology
of various diseases [6]. Free radicals are extremely reactive
and participate in chain reactions that cause other
molecules to become unstable, which generate even
more free radicals [5].
ROS comprise both free radical and non-free radical
oxygen-derived reactive molecules. ROS are constantly
generated, as part of normal aerobic life, during the
intermediate steps of oxygen reduction along the
mitochondrial electron transport chain [7]. Formation of
ROS also occurs as necessary intermediates during various
enzymatic reactions. Common forms of ROS include
superoxide anion radical (O2
•-), hydroxyl radical (•OH),
hydrogen peroxide (H2O2) and singlet oxygen (
1O2).
Reactive nitrogen species (a subset of ROS) include nitric
oxide (NO•) and the peroxynitrite anion (ONOO−) [8].
ROS in high concentrations cause cellular toxicity and can
impair the spermatozoon’s ability to fertilize the oocyte
[9]. However, small amounts of ROS are required for the
regulation of various gamete functions [10,11].
Oxidative stress develops upon an imbalance between
systemic production of ROS and the ability to either
readily detoxify ROS (antioxidant defenses) or repair the
ensuing damage resulting from lipid peroxidation, DNA
damage and apoptosis [12]. Prevention of oxidative
stress is vital in order to maintain normal reproductive
function [13]. Both male and female reproductive systems
possess antioxidant defense mechanisms that facilitate
the quenching of ROS, and maintain equilibrium be-
tween pro- and anti-oxidants. This confers protection
from oxidative damage to the gonadal cells and gametes,
which is vital in the upkeep of normal reproductive
function.
Oxidative stress in the ART setting
Despite the advancement of ART techniques, gametes
and embryos when handled, prepared and manipulated
for ART procedures, are exposed to various potential
ROS-inducing factors. In vitro, the risk of oxidative
stress development is greater than in vivo [13] and its
negative impact may be amplified due to the lack of
physiological defense mechanisms, absence of naturalantioxidants and the presence of multiple potential sources
of ROS [4]. These sources of ROS during ART procedures
could either be endogenously from gametes or via exogen-
ous environmental factors [5]. However, unless measures
are taken to curb ROS production, both the endogenous
and exogenous sources of ROS will ultimately lead to the
development of oxidative stress, which would then nega-
tively impact on fertilization rates and pregnancy outcome.
Sources of ROS
In vivo
Spermatozoa, oocytes and embryos rely on mitochondrial
oxidative phosphorylation for energy, a process which is
subsequently accompanied by ROS generation [5].
Originating from the male Normal human spermatozoa
function such as maturation, capacitation, hyperactivation,
acrosome reaction and oocyte fusion are facilitated by
physiological levels of ROS [14]. However, excess ROS is
detrimental to the spermatozoa functionality and could
lead to male infertility [15]. In human semen, immature
spermatozoa and leukocytes are the two main endogenous
potential sources of ROS [16]. Spermatozoa are particularly
susceptible to oxidative stress as its cell membranes are rich
in polyunsaturated fatty acids, making it more vulnerable
to oxygen-induced damage and lipid peroxidation.
Furthermore, mature spermatozoa lack cytoplasmic
enzymes and antioxidant defense mechanisms [17].
Immature spermatozoa During spermatogenesis dam-
aged spermatozoa undergo arrested spermiogenesis. This
causes them to maintain excess residual cytoplasm, which
can activate the NADPH system. As such, spermatozoa
with cytoplasmic droplets act as a potential contributor to
ROS production [18]. Immature spermatozoa with excess
cytoplasm around its midpiece are functionally defective
having impaired motility and abnormal morphology, which
impacts negatively on its fertilization potential [19].
Leukocytes Leukocytes are the predominant source of
ROS during spermatozoa preparation, as they are able to
produce up to 1000 times more ROS than spermatozoa
in human semen [20,21]. Originating from the prostate
gland and seminal vesicles, peroxidase-positive leukocytes
include polymorphonuclear leukocytes and macrophages
[22]. During infection or inflammation processes in vivo,
leukocytes release large amounts of superoxide when con-
quering pathogens [4]. Seminal leukocytes also stimulate
spermatozoa to produce ROS [3].
Varicocele Varicocele is the abnormal dilatation of veins
in the pampiniform plexus surrounding the spermatic
cord. It is believed to be the most common and treatable
cause of male factor infertility, however a recent Cochrane
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the quality of the available evidence is very low [23].
Varicocele of a higher grade is associated with greater
amounts of seminal ROS [24]. Infertile men with varicocele
have increased oxidative stress levels and lowered antioxi-
dant concentrations [25].
Originating from the female Physiological levels of ROS
are likely to play a role in several aspects of female
reproduction including ovarian steroidogenesis, oocyte mat-
uration, folliculogenesis, ovulation and luteolysis [26,27].
Oocyte Oocyte quality is correlated with 8-hydroxy-2’-
deoxyguanosine (8-OHdG) (a biomarker of oxidative stress
induced-DNA damage) levels in granulosa cells [28]. Poor
oocyte quality would lead to compromised embryo devel-
opment. In the oocyte, ROS levels when present in excess,
can disrupt the oocyte cytoskeleton, alter microtubule
function, cause chromosomal scattering and aneuploidy
[5]. These effects could negatively impair ART outcome.
Cumulus mass cells Cumulus cells originate from
relatively undifferentiated granulosa cells. The cumulus
oophorus encircles the oocyte and is made up of the
cumulus cells and extracellular matrix [29]. Cumulus cells
closely interact and provide support to the developing and
maturing oocyte, shares the oocyte’s microenvironment
and minimize damage by ROS. Cumulus cells are able
to produce antioxidants, such as superoxide dismutase
(SOD), which are suggested to protect the oocyte from
ROS-induced damage [30]. Higher SOD levels in cumulus
cells are associated with ART outcome success [31].
Increased levels of 8-OHdG (an oxidative stress by-product)
in cumulus cells yielded lower oocyte fertilization rates and
poorer embryo quality [28].
Follicular fluid Follicular fluid is secreted by the follicular
theca and granulosa cells, and fills the antral follicle. Low
levels of follicular fluid ROS may be used to predict poten-
tial success of IVF [32,33]. Pregnancy outcome after ICSI is
negatively associated with high levels of follicular fluid
ROS, but is positively associated with follicular fluid total
antioxidant capacity [34]. The ROS upper reference limit
above which viable embryo formation became unsatisfac-
tory was calculated to be around 107 cps/400 μl follicular
fluid in women with tubal factor infertility, endometriosis
and polycystic ovarian syndrome (PCOS). Not only was
fertilization rate and percentage of grades I and II embryo
formation higher in those patients with follicular fluid ROS
levels less than the set limit, when compared to those
above the limit, but DNA fragmented embryos were also
significantly lower [35]. As such, the ROS level in follicular
fluid seems to provide an indication of embryo formation
and quality [36].Originating from the embryo The fast developing em-
bryo produces energy via ATP generation through mito-
chondrial oxidative phosphorylation and glycolysis. As it
develops, the embryo is capable of producing ROS
through several pathways, namely oxidative phosphoryl-
ation, NADPH and xanthine oxidase systems [37]. ROS
generation is particularly excessive during embryonic
genome activation, embryonic compaction and hatching
as these processes demand greater amounts of energy
[38]. Conversely, embryos exposed to high ROS levels are
of lower quality and run the risk of early embryonic
developmental block and retardation [39]. Although
ROS production was reportedly greater in embryos
cultured in vitro compared to those developing in vivo
[40], it remains uncertain if and how much the ART
procedure itself (techniques and conditions employed)
contributed to the higher levels of oxidative stress [5].
In vitro
Figure 1 depicts the potential sources of ROS and oxidative
stress in vitro in a typical clinical ART setting.
Visible light In vitro handling of gametes and embryos
involves the inevitable exposure to visible light
(400–700 nm), from both microscope and from ambient
lighting (laboratory/fluorescent light and daylight/indirect
sunlight) [41,42]. Light within the visible spectrum (visible
light) has detrimental effects on gametes and developing
embryo. The negative impact of visible light is influenced by
duration of exposure, intensity and spectral composition of
light [42].
Blue light (400-500 nm) is particularly more damaging
than visible light with longer wavelengths, as blue light
could generate hydrogen peroxide and alter enzymes in
the respiratory chain [43,44]. Mouse embryo exposed to
blue light had reduced blastocyst formation rates, higher
blastomeric apoptosis rates and higher ROS production in
morula [45]. The use of light filters on inspection micro-
scopes (which cuts off light <500 nm) [42,46], illumination
levels kept at a minimum without compromising visual
inspection and shorter inspection time could help curb
these effects [42].
Light exposure is measured as units of illumination
intensity (lux) or by the level of irradiation (W/m2). Using
low illumination levels (100 lux from microscope, 20
lux from ceiling) during human embryo manipulation
throughout in vitro fertilization-embryo transfer (IVF-ET)
procedures (and other measures to minimize oxidative
stress development in vitro) in 110 IVF cycles yielded a
relatively high blastulation rate [46].
In a recent in vitro study, porcine parthenogenetically-
activated embryos that were developed in culture medium
with prior 24 h-exposure to ambient light yielded a
higher percentage of blastocysts with poor morphology
Figure 1 Potential sources of oxidative stress in vitro in a typical clinical ART setting. In a typical ART setting, the potential sources of
oxidative stress in vitro include endogenous and exogenous (external/environmental factors). The gametes and pre-implantation embryo have the
potential to generate ROS (endogenous sources). Exogenous factors such as visible light; centrifugation, cryopreservation (freeze/thawing), culture
media; oxygen concentration, pH and temperature; and the in vitro fertilization-embryo transfer technique/process itself contributes to ROS
production during ART.
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to ambient light formed fewer and lower quality blastocysts.
This detrimental effect of light exposure on blastocysts was
found to increase with time [41]. Several other studies have
documented the negative impact of visible light exposure
on animal embryo development [43,47-50].
Light irradiation (40 mW/cm2 visible light or 400 to
800 nm with maximum energy at 600 nm for 3 minutes)
of human spermatozoa in capacitation media increased
hyper-activated motility, without enhancing total motility
[51]. As hyper-activated motility escalates the swimming
speed of spermatozoa and helps produce adequate
penetration force [52], development of hyper-activated
motility during the spermatozoa capacitation process may
be critical to ensure successful fertilization [53]. However,
production of ROS in these spermatozoa increased upon
1 to 3 minutes of light exposure [51].
Culture media The composition of media used during
the culture of human oocytes and pre-implantation
embryos has a direct influence on embryo quality and
subsequently ART success [11]. Presence of metallic
ions (iron, Fe2+ and copper, Cu2+) in culture media could
trigger ROS-generating reactions within the cells [37], and
the rate of ROS formation varies with the composition
of culture media [35]. Addition of metal chelators
(e.g. EDTA) may reduce ROS formation [54,55], however,
additional supplements (e.g. albumin) may instead cause a
build-up of oxygen load [5]. Supplementation of cul-
ture media with antioxidants (e.g. ascorbic acid, alpha-
tocopherol) could help alleviate the adverse effects of ROS
on gametes [56]. Key findings of studies using antioxidants
in vitro in media are summarized in Table 1.
pH and temperature Intracellular homeostasis is highly
susceptible to changes in pH (most occur within a
pH of 6 to 8), especially key processes such as protein
synthesis, mitochondrial function, cytoskeletal regulation
and cellular metabolism [68]. Fluctuations of hydrogen
ion concentration (pH) in culture media could negatively
impact spermatozoa motility, oocyte maturation and
embryo development [68,69]. Thus, to maintain the pH of
culture media, incubator CO2 levels should be kept stable,
as low CO2 levels tend to increase the pH of culture
media [68]. Increases in pH could subject cells to oxidative
stress conditions.
The use of buffers in media helps with pH maintenance,
such as sodium bicarbonate during IVF procedures, and
HEPES buffer for storage and handling of spermatozoa
[68]. In case of room temperature-procedures such as
collection of gamete, cryopreservation, ICSI and embryo
transfer, external pH outside of the incubator is maintained
by including another pH buffer along with handling media
containing lower bicarbonate levels [68].Incubator temperature should also be constantly main-
tained at human body temperature [70], as increasing
temperatures decrease pH and pKa levels [71], disrupt
intracellular processes and may further cause ROS-induced
cellular damage [72].Oxygen concentration During IVF and ICSI, pre-
implantation embryos are cultured in the ART laboratory,
commonly under the oxygen concentration of either
atmospheric (~20%) or low (~5%) oxygen concentrations
in vitro [73]. Compared to atmospheric (~20%) oxygen
concentrations, embryo culture in lower (~5%) oxygen
concentrations closer resembled physiological oxygen
concentration in the oviduct and uterus (~2% to 8%)
[73]. Hyperoxic conditions could enhance the activity
of oxygen-dependent oxidase enzymes [37]. Thus, oxygen
concentrations at atmospheric levels could generate ROS
and cause the development of oxidative stress [74], thus
negatively impacting embryo quality.
A Cochrane systematic review (7 studies, 2422 partici-
pants) and meta-analysis (4 studies, 1382 participants) re-
ported that embryos developed better and were of higher
quality when cultured in low (5%) oxygen concentrations,
leading to improved ongoing and clinical pregnancy rates,
and live birth rates. Thus, embryo culture in low (~5%)
oxygen concentrations improves IVF/ICSI success rates
and results in the birth of healthier babies [75]. Even
among poor responders of IVF and ICSI cycles, embryos
developed at low (5%) oxygen concentrations resulted in
higher pregnancy rates [76,77].
In an earlier meta-analysis of 7 randomized controlled
trials (RCTs) comparing the effects of oocyte/embryo
culture at low (~5%) and atmospheric (~20%) oxygen
concentrations, embryos transferred on days 2 or 3 had
similar implantation rates while embryos transferred on
days 5 or 6 (blastocyst stage) had significantly higher
implantation rates when cultured in 5% oxygen concen-
tration. However, in this study, ongoing pregnancy rates
were similar regardless of the oxygen concentration (~5%
or ~20%) or day of transfer (days 2/3 or days 5/6) [78].Centrifugation In ART, centrifugation is a routine step
used in spermatozoa preparation techniques to remove
seminal plasma, which is a potential source of ROS [79].
However, the centrifugation process itself contributes to
ROS levels, with the length of centrifugation time having a
greater influence in inducing-ROS formation compared to
the g-force applied [79]. Despite the initial spermatozoa
quality, longer time of centrifugation exposes spermatozoa
to higher temperature and causes greater detriment to
sperm parameters [80]. Thus, during spermatozoa prepar-
ation protocols, addition of antioxidants such as pentoxifyl-
line [81] in advance of the centrifugation step, could reduce
Table 1 Study outcomes involving in vitro supplementation of various antioxidants during ART protocol
Antioxidant Study type Patient
population
Intervention
(therapeutic
approach)
Control group
(daily dose)
Outcome/effect of
intervention/effect
on parameters
Reference
Vitamin E Prospective Sperm from
normozoospermic
and asthenozoospermic
men
5 mM vitamin E
added to
cryoprotective
media prior to
freeze-thaw
procedure
1. Improvement
in post-thaw motility
Kalthur et al.
[57]
2. Improvement in
DNA integrity
Vitamin E Prospective Sperm from
normozoospermic
men and men
with abnormal
sperm parameters
100 μmol or 200 μmol
vitamin E added to
cryopreservation media
Improved post-thaw
motility of cryopreserved
sperm from men with
both normal and abnormal
sperm parameters
Taylor et al.
[58]
Vitamin E
(alpha-
tocopherol)
Prospective Sperm from
teratozoospermic
men (n = 15)
Sperm prepared by
swim up incubated
with 40 μmol
alpha-tocopherol
added to media x
1 hour
1. Improved sperm motility Keshtgar et al.
[59]
2. Increased sperm viability
Vitamin C Prospective Sperm from male
volunteers with
teratozoospermia
(n = 15)
Sperm prepared by
swim up incubated
with 600 μmol
vitamin C added
to media x 1 hour
1. Reduced MDA levels Fanaei et al.
2014 [60]
2. Reduced DNA damage
3. Improved sperm
progressive motility
4. Improved sperm viability
Vitamin C Prospective DNA damaged
sperm from
infertile men
10 mM ascorbic
acid added to
semen sample
prior to adding
cryomedia
Unsupplemented
cryomedium
1. No change in
post-thaw sperm
concentration or
morphology
Branco et al.
[61]
2. Reduced
number of sperm with
cryopreservation-induced
DNA damage in infertile men
Vitamin C Prospective Sperm from patients
undergoing semen
analysis (n = 134)
Supplementation
of cryomedium
with ascorbate
or 100 μmol/L
AA2G (ascorbic
acid-2-glucoside)
(stabilized form
of ascorbate)
Unsupplemented
cryomedium
Improved post-thaw
sperm motility
Jenkins et al.
[62]
Coenzyme
Q10
Prospective Sperm from
asthenozoospermic
men (n = 22)
HAM’s medium
alone, HAM’s
medium +1%
DMSO, HAM’s
medium +5 μM
CoQ10 or 50 μM
CoQ10 x 24 hours
Samples with
normal motility
sperm (n = 16)
50 μM CoQ10 increased sperm
motility of asthenozoopsermic
men in vitro
Lewin &
Lavon [63]
Melatonin Experimental Sperm from
both healthy
and infertile
men (n = 12)
Sperm
co-incubated
with 1 mM
melatonin x
30 minutes
No treatment 1. Increased percentage
of motile and progressively
motile cells
Ortiz et al.
[64]
2. Increased sperm
vitality and sperm
with normal
morphology
Melatonin Experimental Sperm from
healthy men
(n = 12)
Sperm co-incubated
with 2 mM melatonin x
120 minutes
No treatment 1. Higher percentage
of motility and
progressive motility
du Plessis et al.
[65]
2. Increased sperm
viability
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Table 1 Study outcomes involving in vitro supplementation of various antioxidants during ART protocol (Continued)
L-Carnitine Experimental Peritoneal fluid
from women
with endometriosis
Frozen metaphase II
mouse oocytes and
embryos in peritoneal
fluid (from endometriosis
patients) incubated with
0.6 mg/mL L-Carnitine
Peritoneal fluid
(from endometriosis
patients) only,
peritoneal fluid
(from tubal ligation
patients as control)
only, human tubal
fluid only,
L-carnitine only
1. Improved
microtubule and
chromosome
structure in oocyte
Mansour et al.
[66]
2. Decreased level of embryo
apoptosis
L-Carnitine Experimental Embryo 0.3 mg/mL or
0.6 mg/mL
L-Carnitine
Embryo culture
medium without
supplementation
1. Improved percentage
of blastocyst development
rate with 0.3 mg/mL
L-carnitine
Abdelrazik et al.
[67]
2. Both 0.3 mg/mL and
0.6 mg/mL L-carnitine
reduced the blocking effect
of actinomycin-D, hydrogen
peroxide or tumor necrosis
factor alpha and reduced
the level of DNA damage
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processed spermatozoa [82].
ART technique In the clinical setting, gamete and em-
bryo manipulation in vitro during ART is a potential
source of ROS production [4]. An IVF procedure involves
long incubation time of spermatozoa, oocyte and its
cumulus cells (which are potential ROS generators) in the
fertilization medium. Conversely, ICSI has a shorter incu-
bation period which involves only one spermatozoon and
an oocyte that has been stripped of its cumulus cells.
Hence, ICSI carries a lower risk of ROS production during
fertilization compared to IVF [6]. However, ICSI carries a
greater risk of exposing oocyte DNA to ROS-induced
damage as there is a risk of transferring a small quantity
of ROS-containing medium along with the spermatozoon
into the oocyte [83]. Despite the selected spermatozoon
having a morphologically-normal appearance, it may carry a
greater risk of having DNA damage as natural spermatozoa
selection are bypassed during the ICSI procedure and specif-
ically more so as this is usually the technique of choice when
spermatozoa quality is poor [84].
Cryopreservation (freeze/thawing) Cryopreservation in-
volves the preservation of gametes/embryos and whole
ovarian or testicular tissues by cooling to sub-zero tempera-
tures followed by thawing for use in ART treatments [85].
Although the use of cryoprotectants and optimized proto-
cols seem to enhance cell viability, the freeze-thaw process
is an extreme stressor that can modify the structure and
integrity of the cell, e.g. spermatozoa plasma membrane
[86]. During cryopreservation, freeze-thaw procedures
increase DNA oxidative damage and fragmentation levels,causing post-thaw spermatozoa to have poorer motility
and viability [87,88].
Antioxidant supplementation protect spermatozoa from
the effects of the freeze-thaw process [89]. For example,
supplementation of cryopreservation medium with
quercetin [90] and catalase [91] seemed to protect sperm-
atozoa from oxidative stress-induced damage during the
freeze-thaw process and caused improvement in
spermatozoa motility, viability and DNA integrity.
Addition of Vitamin E [58] and pentoxifylline [92-95]
respectively to cryopreservation medium/prior to cryo-
preservation improved post-thaw motility. Supplementa-
tion of spermatozoa preparation medium with biotin
enhanced the motility of frozen-thawed spermatozoa and
prolonged its survival [96]. Post-thaw spermatozoa quality
is also influenced by the cryopreservation technique and
type of cryoprotectant used [97]. Figure 2 depicts the
effects of oxidative stress and possible interventions to
overcome its detrimental effects at different ART steps.
However, the use of newer cryopreservation techniques
such as vitrification has yielded vitrified oocytes that are
as viable as fresh oocytes in terms of implantation rate,
embryo survival rate and clinical pregnancy rate [98]. A
controlled-randomized clinical trial confirmed that vitrifi-
cation is an effective form of oocyte cryo-storage and is
not inferior to the use of fresh oocytes [99]. This opens a
favorable avenue for patients seeking fertility preservation
or those at risk of ovarian hyperstimulation syndrome.Antioxidants as ameliorating agents
In order to maintain physiological ROS levels and prevent
oxidative stress development, excess ROS must be con-
tinuously neutralized. Antioxidants are able to neutralize
Figure 2 Effects of oxidative stress (OS) and interventions to overcome its effects at different ART steps. Overproduction of ROS could
potentially occur at various steps during ART, leading to oxidative stress. Exposure of the developing embryo to oxidative stress may cause 2 cell
block, reduction in blastomere numbers and blastocyst development rate, apoptosis and fragmentation of the embryo, leading to pre-implantation
embryonic death. However, the appropriate intervention could be taken at various steps during ART to minimize the harmful effects of oxidative stress
on ART outcome. These include: using a lower sperm concentration, shorter co-incubation periods, employment of appropriate sperm preparation
techniques, the use of low levels of illumination and oxygen concentration, use of appropriate type and content of media, including supplementation
with antioxidants.
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termination of propagative oxidative chain reactions
or by scavenging existing ROS, thereby maintaining the
delicate pro-oxidant/anti-oxidant balance and consequently
protecting the cell and its microenvironment from oxida-
tive damage [4,100]. Examples of antioxidant systems
include enzymes such as SOD, catalase and glutathione
peroxidase/reductase, and a variety of non-enzymes such as
vitamins (E, C, B complex), polyphenols (flavonoids), carot-
enoids and trace minerals among others [15]. Components
of the human reproductive system contain antioxidants that
are either endogenously formed or acquired from dietary
sources [13]. In females, antioxidants are present in the
ovary, follicles, follicular, tubal and peritoneal fluid, and
endometrial epithelium [6], while in males, antioxidants are
found in the testis, epididymis, secretions of the male
accessory organs and seminal plasma [17].In an ART setting, antioxidants can be employed to
ameliorate the harmful effects of excess ROS on gametes
and embryos. Treatment strategies using antioxidants
may be approached in two general modes, either as oral
supplementation of the subfertile couple several months
prior to their ART cycle, or as in vitro supplementation
in media during the ART protocol itself, in order to
minimize endogenous and exogenous sources of
ROS, respectively. The role of antioxidants in assisted
reproduction is indeed one of great importance. For
example, in infertile men undergoing IVF and ICSI,
high seminal ROS levels correlate negatively with
spermatozoa morphology and vitality, and fertilization
rates, while seminal antioxidant levels showed a positive
correlation with fertilization rates. Although ROS levels
were higher in IVF than in ICSI patient groups, total anti-
oxidant concentration in seminal plasma and fertilization
Agarwal et al. Reproductive Biology and Endocrinology 2014, 12:112 Page 9 of 19
http://www.rbej.com/content/12/1/112rates did not differ between the IVF and ICSI cohorts [9].
Seminal antioxidants, in general enhance spermatozoa
quality leading to higher ART success rates. Tables 2 and 3
contain a summary of key findings of studies using oral
supplementation of antioxidants respectively in men and
in women.
Enzymatic antioxidants
In normozoospermic men, higher seminal activities of
enzymatic antioxidants correlate with lower total malon-
dialdehyde levels (MDA), indicating the protective effect
of these antioxidants against oxidative stress-induced lipid
peroxidation [133,134]. Conversely, infertile men with
poor spermatozoa quality have lower levels of seminal
enzymatic antioxidants that correspond with increased
levels of lipid peroxidation [133,135].
Superoxide dismutase
Isoforms of SOD found in mitochondria (manganese
SOD) and cytoplasm (copper/zinc SOD) provide funda-
mental defense against ROS [136]. Normozoospermic
men have higher seminal SOD activity compared to men
with abnormal sperm parameters. Seminal SOD activity
correlates positively with spermatozoa concentration and
motility and inversely with both sperm DNA fragmenta-
tion and semen volume [137,138]. SOD activity is
present in granulosa and theca interna cells of pre-
antral, antral and in dominant follicles, with increasing
expression towards ovulation [139]. Women with tubal
factor infertility who failed to conceive had lower SOD ac-
tivity in their granulosa cells and a reduction in embryo
quality [140]. Furthermore it was shown that higher
SOD activity in cumulus cells from women with in-
fertile partners lead to better ART outcome. Thus,
SOD activity may be indicative of a better quality oo-
cyte during oocyte selection [31].
Catalase
Found in cellular peroxisomes, catalase decomposes
hydrogen peroxide to oxygen and water [141]. Catalase,
originating mainly from the prostate gland, is present in
seminal fluid and motile spermatozoa [142]. Low seminal
catalase activity poses a greater risk of post-fertilization
failure in infertile couples undergoing IVF [143]. Catalase
added to spermatozoa preparation media resulted in
reduced ROS and DNA fragmentation levels and an
increased acrosome reaction rate in spermatozoa from
normozoospermic men [144]. During spermatozoa
cryopreservation, supplementation of cryomedia with
catalase gave better freeze-thaw outcomes, with higher
spermatozoa motility, vitality and lesser DNA damage
[91,145]. Similarly, co-supplementation of cryopreserved
spermatozoa with catalase and SOD gave higher post-thaw
motility and viability [146].Glutathione system
The glutathione enzymatic family comprises reduced
glutathione (GSH), glutathione peroxidase (GPx, iso-
forms Gpx 1 to GPx 6), glutathione-S transferase (GST)
and glutathione reductase (GR). GSH is a non-enzymatic
antioxidant peptide formed in the cytosol from glycine,
cysteine, and glutamate. GSH is oxidized to gluthathione
disulphide (GSSG) by GPx. There are 6 isoforms of GPx:
the selenocysteine-containing GPx1 to GPx4, and selenium-
independent GPx5, which is present in the epididymis.
All GPx isozymes reduce hydrogen peroxide and lipid hydro-
xyperoxides [147,148]. Seminal GPx activity is lower in
infertile men with abnormal spermatozoa quality, but
no correlation was found between GPx levels and
spermatozoa fertilization potential or pregnancy rates in
IVF [149].
Non-enzymatic antioxidants
Vitamins and vitamin-like substances
Vitamin E Vitamin E is a naturally-occurring, lipid-
soluble antioxidant. It’s most active form, alpha-tocopherol
quenches hydrogen peroxide, superoxide anion, hydroxyl
anions and breaks peroxidation chain reactions. RCTs and
prospective studies concur that oral supplementation of
vitamin E reduces lipid peroxidation damage [102,150],
improves sperm motility [102,103] and function [101] as
well as improve fertilization [150] and pregnancy rates
[102,103]. In a small prospective study (n = 15), Geva’s
group showed that oral vitamin E (200 mg for 3 months)
increased oocyte fertilization rate per IVF cycle in fertile,
normozoospermic men who initially had low fertilization
rates during a previous IVF attempt. Following antioxidant
therapy with vitamin E, these men also experienced lower
lipid peroxidation levels in their spermatozoa [150]. In
women with unexplained infertility, oral vitamin E intake
improved the endometrial response, possibly due to
its antioxidant and anticoagulant effects as well as by
modulating the anti-estrogenic effect of clomiphene
citrate. However, no differences in implantation or
pregnancy rates were observed [122]. The in vitro effects
of vitamin E on normal and abnormal spermatozoa
during cryopreservation are improved post-thaw motility
[57,58] and DNA integrity [57], while addition during
incubation improved motility and viability of abnormal
spermatozoa [59].
Selenium, an essential micronutrient and a free
radical-scavenger, works synergistically with Vitamin E
to protect spermatozoa from the effects of oxidation
[104] and to improve motility [104,105], morphology
and pregnancy rates [105]. Found in high concentrations
in testicular tissue, selenium is required for testosterone
synthesis and spermatogenesis [151,152]. Moslemi and
Tavanbakhsh studied the effects of vitamin E and selenium
Table 2 Study outcomes involving oral supplementation of various antioxidants in men
Antioxidant Study type Patient population Intervention (daily
dose x duration)
Control group
(daily dose)
Study outcome (effect
on sperm parameters)
Reference
Vitamin E Double blind,
placebo cross-
over, RCT
Healthy men with
high seminal ROS
levels (n = 30)
600 mg vitamin E x
3 months (n = 15)
Placebo
(n = 15)
Improved in vitro sperm
function (improved zona-
binding assay)
Kessopoulou
et al. [101]
Vitamin E Double blind,
placebo-
controlled
Men with (n = 110)
asthenozoospermia or
oligoasthenozoospermia
300 mg vitamin E x
6 months (n = 52)
Placebo
(n = 55)
1. Reduced MDA concentration
(less LPO in spermatozoa)
Suleiman
et al. [102]
2. Improved sperm motility
3. 20% of those on therapy
achieved pregnancy
Vitamin E +
Anti-Estrogen
(Clomiphene
citrate)
Prospective,
placebo-
controlled RCT
Infertile men
with idiopathic
oligozoospermia
(n = 60)
400 mg vitamin E
+25 mg clomiphene
citrate x 6 months
(n = 30)
Placebo
(n = 30)
1. Improved sperm count and
progressive motility
Ghanem
et al. [103]
2. Partners had higher incidence
of pregnancy
Vitamin E +
selenium
Open,
randomized
Volunteers and
infertile men
(n = 54)
400 mg vitamin E
+225 μg selenium x
3 months (n = 28)
4.5 g
vitamin B x
3 months
(n = 26)
1. Reduced MDA concentration
(less LPO in spermatozoa)
Keskes-Ammar
et al. [104]
2. Improved sperm motility
Vitamin E +
selenium
Observational
study
Infertile men
with idiopathic
asthenozoospermia
(n = 690)
400 IU vitamin E
+200 μg selenium x
100 days
None 1. Improvement in sperm
motility/morphology or both
(53%)
Moslemi &
Tavanbakhsh
[105]
2. Increased spontaneous
pregnancy rates (11%)
Vitamin E +
Vitamin C
Double blind,
placebo-
controlled, RCT
Men (n = 31) with
asthenozoospermia
or moderate
oligoasthenozoospermia
1000 mg vitamin C
+800 mg vitamin E x
8 weeks (n = 15)
Placebo
(n = 16)
No improvement in sperm
parameters
Rolf et al.
[106]
No improvement in 24 h sperm
survival rate
Vitamin E +
Vitamin C
Observational
study, double-
blind
Men with elevated
sperm DNA
fragmentation
(≥15%) who have
unexplained infertility
1000 mg vitamin C
+1000 mg vitamin E x
2 months (n = 32)
Placebo
(n = 32)
Reduced percentage of
DNA-fragmented sperm
(TUNEL test)
Greco et al.
[107]
Vitamin E +
Vitamin C
Observational
study
involving
assisted
conception
treatment
Men with elevated
sperm DNA
fragmentation
(≥15%) who failed
their 1st ICSI attempt
1000 mg vitamin C
+1000 mg vitamin E x
2 months (n = 38)
None 1. Reduced percentage of
DNA-fragmented sperm
(TUNEL test)
Greco et al.
[108]
2. Marked improvement in
implantation and clinical
pregnancy rates in the 2nd ICSI
attempt vs 1st attempt
Vitamin C Men with sperm
agglutination
(>25%) (n = 30)
200 mg vitamin C or
1000 mg vitamin C
Placebo Improved sperm motility,
viability, morphology after
4 weeks (more prominent
improvement in 1000 mg
vitamin C vs. 200 mg vitamin C)
Dawson et al.
[109]
Vitamin C Men who are heavy
smokers (n = 75) with
normal reproductive
function
200 mg vitamin C or
1000 mg vitamin C
Placebo 1. Improved sperm
agglutination
Dawson et al.
[110]
2. Improved 24 h viability
3. Improved sperm morphology
Folic acid +
zinc sulphate
Double blind,
placebo-
controlled, RCT
Fertile (n = 108) and
subfertile men (n = 103)
5 mg folic acid, 66 mg
zinc sulphate or 5 mg
folic acid +66 mg zinc
sulphate x 26 weeks
Placebo or
placebo +
placebo
Increased sperm concentration
in subfertile and fertile males
after combined treatment
Wong et al.
[111]
Folic acid +
zinc sulphate
Double blind,
placebo-
controlled
Fertile (n = 47) and
subfertile men (n = 40)
5 mg folic acid +66 mg
zinc sulphate x 26 weeks
Placebo Increased sperm concentration
in infertile males, but not fertile
males
Ebisch et al.
[112]
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Table 2 Study outcomes involving oral supplementation of various antioxidants in men (Continued)
Folic acid +
zinc sulphate
Double blind,
placebo
controlled, RCT
Subfertile men with
OAT (n = 83)
5 mg folic acid +220 mg
zinc sulphate x16 weeks
Placebo Zinc sulfate + folic acid did
not improve sperm quality
in men with OAT (severely
compromised sperm
parameters)
Raigani et al.
[113]
Folic acid +
zinc sulphate
Prospective,
randomized
controlled
Men with palpable
varicocele (grade III)
who underwent
surgical repair of
varicocele (n = 160)
5 mg folic acid (n = 26),
66 mg zinc sulphate
(n = 32) or 5 mg
folic acid +66 mg
zinc sulphate (n = 29)
x 6 months
Placebo
(n = 25)
1. Zinc sulfate + folic acid
improved sperm parameters
and improved varicocelectomy
outcomes
Azizollahi
et al. [114]
2. Improved protamine
content and halo formation
rate
Coenzyme
Q10
Systematic
review and
meta-analysis
(3 RCTs)
Infertile men CoQ10 (n = 149) Controls
(n = 147)
1. Improved seminal
CoQ10 levels
Lafuente
et al. [115]
2. Increased sperm
concentration
3. Increased sperm motility
4. No increase in pregnancy
rates
5. Data on live births were
lacking
Coenzyme
Q10
Double
blind, placebo-
controlled, RCT
Men with iOT
(n = 60)
200 mg CoQ10 x
3 months (n = 30)
Placebo
(Lactose)
(n = 30)
1. Increased levels of
CoQ10 in seminal
plasma
Nadjarzadeh
et al. [116]
2. Decreased 8-isoprostane
levels (biomarker of LPO)
(attenuation of OS in seminal
plasma)
3. Increased sperm forward and
total motility
4. Increased catalase, SOD
activity
Coenzyme
Q10
Double
blind, placebo-
controlled, RCT
Men with iOAT
(n = 47)
200 mg CoQ10 x
12 weeks
Placebo 1. Reduced TBARS (reduced
plasma MDA levels)
Nadjarzadeh
et al. [117]
2. Increased TAC in seminal
plasma
Coenzyme
Q10
Double
blind, placebo-
controlled, RCT
Men with iOAT
(n = 228)
200 mg ubiquinol x
26 weeks (n = 114)
Placebo
(n = 114)
Improved sperm quality
(density, motility, normal
strict morphology)
Safarinejad
et al. [118]
Coenzyme
Q10
Double
blind, placebo-
controlled, RCT
Men with idiopathic
infertility (n = 60)
200 mg CoQ10 x
6 months
Placebo 1. Increase in CoQ10
and ubiquinol in seminal
plasma and spermatozoa
Balercia
et al. [119]
2. Increase in spermatozoa
motility
Coenzyme
Q10
Prospective Men with iOAT
(n = 212)
300 mg CoQ10 x
26 weeks (n = 106)
Placebo
(n = 106)
1. Improved sperm density,
motility, normal strict
morphology
Safarinejad
[120]
2. Improved acrosome reaction
Coenzyme
Q10
Open-label,
prospective
Men with iOAT
(n = 287)
600 mg CoQ10 x
12 months (n = 106)
None 1. Improved sperm quality
(concentration, progressive
motility, normal morphology)
Safarinejad
[121]
2. Improved pregnancy rates
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fertile men from couples with male factor infertility. Semen
analysis was found to be improved in 362 or 52.6% pa-
tients: 299 patients showed improved motility, 21 patientsshowed improved morphology and 42 patients showed
improvement in both sperm motility and morphology.
However, 253 cases (36.6%) showed no change in their
semen analysis, while the remaining 75 patients (10.8%)
Table 3 Study outcomes involving oral supplementation of various antioxidants in women
Antioxidant Study type Patient
population
Intervention (daily
dose x duration)
Control group
(daily dose)
Study outcome Reference
Vitamin E Women with
unexplained
infertility
undergoing
ovarian
stimulation
and then IUI
400 IU/day vitamin E 1. Increased endometrial thickness Cicek et al.
[122]
2. No significant increase in
implantation and pregnancy rates
Vitamin C Prospective Women
undergoing
IVF-ET (n = 76)
500 mg vitamin C/day
(slow release) to women
smokers (n = 19) and
women non-smokers
(n = 19)
Placebo Women non-smokers had higher
pregnancy rates than women smokers
Crha et al.
[123]
Vitamin C Prospective,
randomized
Infertile women
with luteal
phase defects
(not on IVF-ET)
750 mg ascorbic acid
(n = 76) started on first
day of third menstrual
cycle until positive urine
pregnancy test
(maximum 6 months)
No treatment
(n = 46)
1. Increase in progesterone levels Henmi
et al. [124]
2. Increase in clinical pregnancy rates
Vitamin C Double blind,
placebo-
controlled, RCT
Women (<40y)
undergoing first
IVF-ET cycles
(n = 620)
1 g or 5 g or 10 g
ascorbic acid +30 mg
Dydrogesteron x 14 days
after follicle aspiration for
IVF-ET
Placebo
(Lactose + citric
acid +30 mg
Dydrogesteron)
No difference in clinical pregnancy
and implantation rates
Griesinger
et al. [125]
Myo-inositol +
folic acid
Placebo-
controlled, RCT
Infertile PCOS
patients
undergoing
ovulation
induction for
ICSI (n = 60)
4 g myo-inositol +400 μg
folic acid (n = 30)
400 μg folic
acid only
(n = 30)
Reduced germinal vesicles and
degenerated oocytes without
compromising the number of
oocytes retrieved at ovum pick-up
Papaleo
et al. [126]
Myo-inositol +
folic acid
Double blind Infertile PCOS
patients
undergoing
ovulation
induction for
IVF or ICSI
(n = 34)
4 g of myo-inositol
+400 μg of folic acid,
continuously for
3 months
400 μg of folic
acid only
1. Greater number of oocytes
recovered during pick up
Ciotta
et al. [127]
2. Greater number of oocytes with
score S1
3. Reduced number of immature
oocytes (vesicles germ and
degenerated oocytes)
Melatonin Follicular fluid
sampled
during oocyte
retrieval
during IVF-ET
Women with
prior failure of
IVF-ET cycle
and who are
attempting
IVF-ET again
(n = 115)
3 mg melatonin (n = 56)
given on the 5th day of
the previous menstrual
cycle until the day of
oocyte retrieval
Without
melatonin
treatment
(n = 59)
1. Improved fertilization rate
compared to previous IVF-ET cycle
Tamura
et al. [128]
2. Improved oocyte quality
Melatonin Prospective,
randomized
Women
with primary
infertility
undergoing
IVF-ET cycles
(n = 85)
3 mg melatonin (n = 40)
administered
continuously from day of
GnRH
No treatment
(n = 45)
1. Higher percentage of morphologically
mature oocytes retrieved (MII oocytes)
Batioglu
et al. [129]
2. Higher mean number of top quality
(class I) embryos
3. No improvement in fertilization rates
4. Higher tendency of clinical pregnancy
rate (not statistically significant)
Melatonin Prospective,
randomized
IVF patients
with disturbed
sleep (insomnia)
who were
undergoing
IVF-ET (n = 60)
3 g melatonin (n = 30)
given 3rd to the 5th day
of the previous menstrual
cycle until the hCG
injection day of the
controlled ovarian
hyperstimulation
No treatment
(n = 30)
1. Higher mean number of the retrieved
oocytes, mean MII oocyte counts, and G1
embryo ratio
Eryilmaz
et al. [130]
2. No change in sleeping status
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Table 3 Study outcomes involving oral supplementation of various antioxidants in women (Continued)
Melatonin +
myo-inositol +
folic acid
Prospective,
randomized
Women
undergoing
IVF cycles
(n = 65)
3 g melatonin +4 g
myo-inositol +200 mg
folic acid (n = 32)
administered
continuously from
day of GnRH
4 g myo-
inositol + folic
acid (n = 33)
1. Greater mean number of mature
oocytes (and lower mean number
of immature oocytes)
Rizzo
et al. [131]
2. Higher mean number of top quality
embryos (class 1 and 2)
3. No improvement in fertilization rates
4. Higher tendency of clinical pregnancy
rate and implantation rate (not
statistically significant)
Melatonin +
myo-inositol +
folic acid
Prospective,
longitudinal,
cohort
Women with
failed IVF cycle
(due to poor
oocyte quality)
who were
undergoing a
new IVF cycle
3 mg melatonin +4 g
myo-inositol +400 mcg
folic acid x 3 months
(n = 46)
Prior cycle of
the same
women but
without
treatment
1. Higher number of morphologically
mature oocytes retrieved (MII oocytes)
Unfer
et al. [132]
2. Higher total number of embryo
transferred and higher number of top
quality (score 1 & 2) embryo transferred
3. Increased fertilization rate
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findings, it seems that a combination of vitamin E
and selenium had a more significant impact on motility
compared to morphology.
Besides selenium, vitamin E is often administered in
combination with vitamin C, another chain breaking
antioxidant. An initial RCT reported that sperm parameters
did not change after co-supplementation with vitamins E
and C [106]. However, subsequent observational studies in
men with poor sperm DNA integrity showed that supple-
mentation with both vitamins E and C resulted in fewer
spermatozoa with fragmented DNA [107,108], as well as
higher implantation and clinical pregnancy rates [108].
Vitamin C Vitamin C (L-ascorbic acid, ascorbate) is a
water-soluble, naturally-occurring, chain-breaking anti-
oxidant. It is unstable, easily oxidized and perishable in
high temperatures [153]. Ascorbic acid taken as dietary
intake [154,155] or oral therapy, improves spermatozoa
quality [109,110]. In a large, placebo-controlled, double
blind RCT, vitamin C supplementation for a period of
14 days starting on the day of follicle aspiration in
women undergoing IVF-ET showed no improvement in
clinical pregnancy or implantation rates [125]. However,
smaller prospective studies showed that oral vitamin C
supplementation in women, either undergoing IVF-ET
treatment [123] or with luteal phase defects [124], lead
to increased pregnancy rates. Addition of vitamin C in
cryomedia improved motility [62] and reduced DNA
damage [61] in post-thaw spermatozoa. Similarly, vitamin C
supplemented culture media reduced lipid peroxidation and
DNA damage, while improving spermatozoa motility and
viability [60].
Vitamin B – folic acid B vitamins form a group of
water soluble antioxidants. Folate (vitamin B9) is the natural
dietary form, while folic acid is its synthetic equivalent.Folate levels in seminal plasma are higher than in serum
and in fertile men compared to infertile men [156,157].
Similarly, fertile men were found to have higher seminal
zinc levels compared to infertile men [158]. As it has been
observed that zinc deficiency decreases the absorption
and metabolism of folate, most studies related to folate is
combined with zinc supplementation. An essential trace
element, zinc acts as a ROS-scavenger and regulates
sperm motility [159]. In men with asthenozoospermia,
intake of zinc sulphate (500 mg for 3 months) improved
spermatozoa quality (count, progressive motility and
fertilizing capacity) and reduced the incidence of antisperm
antibodies [160].
Double-blind, placebo-controlled, RCTs investigating
the effects of combined folic acid and zinc sulphate oral
treatment in infertile men report an increase in sperm
concentration [111,112], but not in those with severe
oligoasthenoteratozoospermia (OAT) [113]. Among
varicocele patients who sought surgical intervention,
combined therapy of folic acid and zinc sulphate improved
sperm parameters and consequently varicocelectomy
outcome [114]. In infertile women with PCOS undergoing
ovulation induction for IVF/ICSI, oral therapy of
myo-inositol (a component of the vitamin B family) and
folic acid reduced the number of immature oocytes during
pick up [126,127].
Coenzyme Q10 Coenzyme Q10 is a vitamin-like, lipid
soluble substance present in most eukaryotic cells as it
forms part of the the mitochondrial respiratory chain.
Coenzyme Q10 may also be present in its oxidized
(ubiquinone) or reduced form (ubiquinol) [161]. Results of
a systematic review and meta-analysis on coenzyme Q10
therapy in male infertility show that oral supplementation
with coenzyme Q10 increased seminal coenzyme Q10
levels, spermatozoa concentration and motility. However,
there was no increase in pregnancy rates while data
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placebo-controlled RCTs using coenzyme Q10 or ubiquinol
therapy in men with idiopathic infertility, study outcomes
also reported of lower lipid peroxidation and oxidative
stress levels in seminal plasma [116,117], increase in sem-
inal enzymatic antioxidant activity [116,117] and ubiquinol
(a potent antioxidant) levels [119]. Prospective studies
on coenzyme Q10 intake in men with idiopathic infertility
reported of improved acrosome reaction [120] and preg-
nancy rates [121]. In infertile men with prior failed IVF/ICSI,
coenzyme Q10 supplementation increased fertilization rates
in the subsequent cycle [63]. The group also found that
adding coenzyme Q10 into media with asthenozoopermic
spermatozoa increased spermatozoa motility [63].
Hormones
Melatonin Melatonin, a powerful antioxidant secreted
by the pineal gland, is present in follicular fluid and
semen. Melatonin also activates the primary enzymatic
antioxidants (SOD, catalase, GPx) [162]. Interestingly
the concentration of melatonin in the pre-ovulatory
follicle is higher than normal plasma melatonin levels
[163]. Intrafollicular melatonin levels also inversely
correlated to 8-OHdG and thus degenerate oocytes [164].
In several prospective randomized studies in infertile
women undergoing IVF-ET cycles, continuous oral mela-
tonin supplementation, starting from the previous men-
strual cycle until ovarian stimulation, improved oocyte
quality, increased the number of mature MII oocytes
retrieved and resulted in a better ratio of top quality em-
bryos [129,130,164]. In other prospective studies, mela-
tonin was given along with myo-inositol and folic acid in
women planning for IVF treatment, which also resulted in
higher number of mature oocytes and top quality embryos
[131,132]. There was a tendency for higher clinical preg-
nancy and implantation rates (although statistically insig-
nificant) [129,131], while fertilization rates were reported
to be either higher [132,164] or without improvement in
[129,131]. However, a systematic review and meta-analysis
of RCTs on melatonin supplementation in women under-
going controlled ovarian stimulation for assisted concep-
tion concluded that the included trials provided low
quality evidence on the parameters examined [165]. In ex-
perimental in vitro studies, spermatozoa from healthy
men incubated with melatonin showed improved motility,
viability [64,65] and higher ratio of spermatozoa with nor-
mal morphology [64].
Other antioxidative substances
Trace element supplementation has shown to improve
sperm quality. For example, in vitro zinc supplementation
to sperm media, either alone or in combination with other
antioxidants (as previously discussed), reduced sperm
DNA fragmentation [166,167], and loss of motility [167].Addition of zinc to cryomedia also protects against
post-thaw loss of spermatozoa function and sperm
DNA damage [168]. In a large double blind placebo-
controlled RCT involving infertile men with idiopathic OAT
(iOAT) combined oral intake of selenium and N-acetyl-
cysteine correlated positively with spermatozoa quality. The
additive effects were significantly better when compared to
either selenium or N-acetyl-cysteine intake [169]. Besides
trace elements, other antioxidants such as L-Carnitine also
play a role in the enhancement of sperm parameters.
Derived from lysine, L-Carnitine is a naturally-occurring
molecule [170] that scavenges ROS. A systemic review
and meta-analysis of 9 RCTs concluded that oral supple-
mentation with L-carnitine or L-acetyl-carnitine improves
total sperm motility and pregnancy rates [171]. In two
separate studies, it was shown that the in vitro addition of
L-carnitine to the culture media not only improved oocyte
chromosomal structure and reduced embryo apoptosis
[66], but also improved blastocyst development rate [67].
Conclusions
A Cochrane review on antioxidant intake in male partners
of couples undergoing ART (34 trials, 2876 couples)
reported increased pregnancy rate (15 trials, 964 couples,
96 pregnancies) (pooled odds ratio (OR) 4.18, 95% CI
2.65-6.59; P < 0.00001, I2 = 0%) and increased live births
(3 studies, 214 couples, 20 live births) (pooled OR 4.85,
95% CI 1.92-12.24); P = 0.0008, I2 = 0%) in men taking oral
antioxidants [172]. On the other hand, a Cochrane review
on oral antioxidant supplementation in women seeking
IVF/ICSI (28 trials, 3548 women) reported of very low
quality evidence indicating that antioxidant intake was
neither associated with increased pregnancy rate (13
trials, 2441 women) (OR 1.30, 95% CI 0.92-1.85; P = 0.14,
I2 = 55%) nor with live birth rate (2 trials, 97 women)
(OR 1.25, 95% CI 0.19-8.26; P = 0.82, I2 = 75%). However,
data from 3 trials (276 women) showed that pentoxifylline
was associated with increased clinical pregnancy rates
(OR 2.03, 95% CI 1.19-3.44, P = 0.009, I2 = 0%) in subfer-
tile women [173]. Both these reviews outlined the need for
better quality evidence that would allow for a more defini-
tive verdict on the usefulness of oral antioxidant therapy
in the ART population.
Along these lines, further large, well-designed randomized
controlled clinical trials on oral supplementation of
antioxidants is required in order to give stronger evidence
and determine more conclusively regarding the safety and
efficacy of antioxidant therapy in improving gamete quality
in infertile males and females as well as couples seeking
ART. Similarly, the use of antioxidants in vitro in the clin-
ical laboratory setting during ART procedures should also
be considered, alongside improvement of ART techniques
and optimization of the laboratory environment. As even
some of the studies that form the basis for the previously
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geneity it is important to note that unrestricted recommen-
dation of antioxidant supplements could even be hazardous
to patients.
Undeniably, excessive ROS leading to oxidative stress
conditions has a serious impact on the outcome of
assisted reproduction, leading to lower fertilization,
implantation and pregnancy rates. As highlighted in
this review, ART procedures in vitro presents with
many avenues for ROS and oxidative stress develop-
ment, which would negatively impair gamete/embryo
quality and consequently reduce ART success. While
the generation of ROS during ART steps cannot completely
be avoided, practical strategies that minimize potential
ROS-inducing factors during the ART procedures, as
portrayed in this paper, are worth exploring.
In conclusion, prophylactic oral antioxidant therapy
and supplementation of medium for culture, incubation/
handling and cryopreservation can possibly help improve
gamete quality and fortify the developing embryo. However,
the appropriate antioxidants and dosages (whether as a sole
compound or as a combination) suitable for different forms
of infertility issues still remain an ongoing area of research.
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